Novartis Keen On Cardio Deals But Obesity Ship Has Sailed

 
• By Kevin Grogan
  
Generate a summary of this article
Listen to this article
Beta

The Swiss major is sticking to a bolt-on M&A strategy in its key areas and a deal in the obesity space is highly unlikely unless it involves "leapfrogging" what is already available.

Novartis Jan 24
• Source: Novartis

Having completed its transformation into a pure-play innovative medicines business in 2023 following the spin-off of the Sandoz business, Novartis AG is on the look-out for more bolt-on deals in its four core therapeutic areas – cardiovascular/renal/metabolic, immunology, neuroscience and oncology – but the likelihood of the Swiss giant jumping into the obesity space is looking faint.

That was the view of chief financial officer Harry Kirsch as he presented Novartis's financials for the fourth quarter to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.